Ipsen's 1st-half 2006 sales rise 7% to $550M
French drugmaker Ipsen says that its first-half 2006 sales reached 430.6 million euros, up 6.6% year-on-year, as revenues from its strategic targeted therapeutic areas rose 14% to 221.8 million euros, representing 51.5% of its total consolidated sales.
In oncology, sales reached 113.6 million euros, up 7.0%, despite price reductions for Decapeptyl (triptorelin), which grew 10% in volume. Revenues from endocrinology products jumped 22% to 52.4 million euros due to the success in the developments of NutropinAq (controlled-release somatropin), which continued to progress satisfactorily, and from Somatuline (lanreotide)/Somatuline Autogel, which confirmed its strong position in all its main markets. Sales of Dysport, Ipsen's botulinum toxin product, remained strong due to favorable market dynamics in the UK, Latin America and the Middle East.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze